专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050049200A1 LHRH-antagonists in the treatment of fertility disorders 有权
标题翻译： LHRH拮抗剂治疗生育障碍
公开(公告)号：US20050049200A1
公开(公告)日：2005-03-03
申请号：US10661780
申请日：2003-09-15
申请人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
发明人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
IPC分类号： A61K38/22 , A61K38/04 , A61K38/09 , A61P13/02 , A61P15/00 , A61K31/4743
CPC分类号： A61K38/09 , C12M21/06
摘要： A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.
摘要翻译：一种通过以下方式治疗不育症：1）以选择性抑制内源性LH而不是FSH分泌的量施用LH-RH拮抗剂，优选Cetrorelix; 2）通过施用外源性促性腺激素诱导卵泡生长。选择性抑制LH允许FSH分泌处于自然水平，从而不影响个体雌激素的发育。 LH-RH拮抗剂可以以1mg至10mg，优选2mg-6mg范围内的单次或双次皮下给药。在多剂量剂量学中，LH-RH拮抗剂可以以0.1-0.5mg LH-RH拮抗剂/天的量皮下施用。 LH-RH拮抗剂在第1至10天开始循环，优选在第4至8天施用，并且可以在月经周期的第9至20天之间通过施用rec来诱导排卵。 LH，天然LH-RH，LH-RH激动剂或HCG。另外rec。可以给予LH，天然LH-RH或LH-RH激动剂以避免过度刺激综合征，并且可以施用天然LH-RH或LH-RH激动剂，以通过中和HCG的负面作用来避免黄体期刺激。

2. 发明申请

US20110306547A1 LHRH - ANTAGONISTS IN THE TREATMENT OF FERTILITY DISORDERS 有权
标题翻译： LHRH - 治疗肥胖症的拮抗剂
公开(公告)号：US20110306547A1
公开(公告)日：2011-12-15
申请号：US12941629
申请日：2010-11-08
申请人： PHILIPPE BOUCHARD , Rene Frydman , Paul Devroey , Klaus Diedrich , Jürgen Engel
发明人： PHILIPPE BOUCHARD , Rene Frydman , Paul Devroey , Klaus Diedrich , Jürgen Engel
IPC分类号： A61K38/24 , A61P15/08 , A61K31/4025 , A61K31/44 , A61K31/4439 , A61K38/22
CPC分类号： A61K38/09 , C12M21/06
摘要： A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural level S thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day . LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralising the negative effects of HCG.
摘要翻译：一种通过以下方式治疗不育症：1）以选择性抑制内源性LH而不是FSH分泌的量施用LH-RH拮抗剂，优选Cetrorelix; 2）通过施用外源性促性腺激素诱导卵泡生长。选择性抑制LH允许FSH分泌处于自然水平S，从而不影响个体雌激素的发育。 LH-RH拮抗剂可以以1mg至10mg，优选2mg-6mg范围内的单次或双次皮下给药。在多剂量药物学中，LH-RH拮抗剂可以以0.1至0.5mg LH-RH拮抗剂/天的量皮下施用。 LH-RH拮抗剂在第1至10天开始循环，优选在第4至8天施用，并且可以在月经周期的第9至20天之间通过施用rec来诱导排卵。 LH，天然LH-RH，LH-RH激动剂或HCG。另外rec。可以给予LH，天然LH-RH或LH-RH激动剂以避免过度刺激综合征，并且可以施用天然LH-RH或LH-RH激动剂，以通过中和HCG的负面作用来避免黄体期刺激。

3. 发明授权

US09107871B2 LHRH—antagonists in the treatment of fertility disorders 有权
标题翻译： LHRH拮抗剂治疗生育障碍
公开(公告)号：US09107871B2
公开(公告)日：2015-08-18
申请号：US12941629
申请日：2010-11-08
申请人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
发明人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
IPC分类号： A61K38/09 , C12M3/00
CPC分类号： A61K38/09 , C12M21/06
摘要： A method for obtaining the production of a fertilizable oocyte within a program of assisted reproduction techniques comprising normal follicular growth and development to proceed in the absence of stimulation by an exogenous gonadotropin, followed by administering an amount of an LHRH antagonist in a dosage regimen that prevents a premature LH surge while maintaining FSH secretion at a natural level and individual estrogen development is not affected.
摘要翻译：一种在辅助生殖技术程序中获得可施肥卵母细胞生产的方法，包括正常的卵泡生长和发育，以在没有外源性促性腺激素刺激的情况下进行，随后在预防剂量方案中施用一定量的LHRH拮抗剂维持FSH分泌在自然水平和个体雌激素发育过早的LH波动不受影响。

4. 发明授权

US07393834B2 LHRH-antagonists in the treatment of fertility disorders 有权
标题翻译： LHRH拮抗剂治疗生育障碍
公开(公告)号：US07393834B2
公开(公告)日：2008-07-01
申请号：US10661780
申请日：2003-09-15
申请人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
发明人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
IPC分类号： A61K38/09 , A61K31/551 , A61K31/4743
CPC分类号： A61K38/09 , C12M21/06
摘要： A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.
摘要翻译：一种通过以下方式治疗不育症：1）以选择性抑制内源性LH而不是FSH分泌的量施用LH-RH拮抗剂，优选Cetrorelix; 2）通过施用外源性促性腺激素诱导卵泡生长。选择性抑制LH允许FSH分泌处于自然水平，从而不影响个体雌激素的发育。 LH-RH拮抗剂可以以1mg至10mg，优选2mg-6mg范围内的单次或双次皮下给药。在多剂量剂量学中，LH-RH拮抗剂可以以0.1-0.5mg LH-RH拮抗剂/天的量皮下施用。 LH-RH拮抗剂在第1至10天开始循环，优选在第4至8天施用，并且可以在月经周期的第9至20天之间通过施用rec来诱导排卵。 LH，天然LH-RH，LH-RH激动剂或HCG。另外rec。可以给予LH，天然LH-RH或LH-RH激动剂以避免过度刺激综合征，并且可以施用天然LH-RH或LH-RH激动剂，以通过中和HCG的负面作用来避免黄体期刺激。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式